Skip to main content

Advertisement

SpringerLink
Log in

The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Objectives

In recent years, docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy (IC) has been widely applied in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). However, it remains unclear whether TPF is the ideal IC regimen. Thus, we carried out a meta-analysis to compare the efficacy and safety of TPF-based IC plus concurrent chemoradiotherapy (CCRT) versus CCRT alone or double-drug-based IC plus CCRT for LA-NPC.

Methods

We systematically searched PubMed, Embase and the Cochrane Library from inception until December 2018. After rigorous screening of all relevant studies that reported the use of TPF-based IC followed by CCRT for patients with LA-NPC, eight studies met the inclusion criteria and were assessed for design and quality. Among them, three articles were classified as having a high risk of bias and were excluded from the meta-analysis. The outcomes, including overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional failure-free survival (LRFFS) and incidence of adverse events, were pooled with the use of hazard ratio (HR) or odds ratio (OR). Heterogeneity and sensitivity analyses were also carried out.

Results

Five trials involving 4223 patients were included in the meta-analysis. Compared to CCRT alone, TPF-based IC plus CCRT significantly improved OS (HR 0.54, 95% confidence interval [CI] 0.35–0.84, P = 0.006), PFS (HR 0.64, 95% CI 0.46–0.88, P = 0.006), LRFFS (HR 0.57, 95% CI 0.34–0.94, P = 0.03), and DMFS (HR 0.58, 95% CI 0.38–0.88, P = 0.01). Moreover, compared to double-drug-based IC plus CCRT, OS (HR 0.74, 95% CI 0.62–0.87, P = 0.0004), PFS (HR 0.76, 95% CI 0.66–0.88, P = 0.0001) and LRFFS (HR 0.75, 95% CI 0.61–0.92, P = 0.006) were also significantly improved by TPF-based IC plus CCRT. Notably, TPF-based IC plus CCRT mainly led to an increased risk of hematologic toxicities, such as leucopenia (OR = 3.20, 95% CI 2.13–4.81, P < 0.0001) and neutropenia (OR = 3.84, 95% CI 0.66–22.36, P = 0.13). However, these were uncomplicated and manageable with growth factor support.

Conclusions

Compared to CCRT alone or double-drug-based IC plus CCRT, TPF-based IC plus CCRT results in better survival outcomes with manageable toxicities. Thus, it is reasonable to recommend the addition of TPF-based IC to CCRT as an excellent choice for patients with LA-NPC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016;387(10022):1012–24.

    PubMed  Google Scholar 

  2. Mao YP, Xie FY, Liu LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73(5):326–1334.

    Google Scholar 

  3. Lee AWM, Lin JC, Ng WT. Current management of nasopharyngeal cancer. Semin Radiat Oncol. 2012;22(3):233–44.

    PubMed  Google Scholar 

  4. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16(4):1310–7.

    CAS  PubMed  Google Scholar 

  5. Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2010;80(3):661–8.

    PubMed  Google Scholar 

  6. Wu F, Wang R, Lu H, et al. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study. Radiother Oncol. 2014;112(1):106–11.

    PubMed  Google Scholar 

  7. Li WF, Chen L, Sun Y, Ma J. Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Chin J Cancer. 2016;35(1):94.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645–55.

    PubMed  Google Scholar 

  9. Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14–23.

    CAS  PubMed  Google Scholar 

  10. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–20.

    CAS  PubMed  Google Scholar 

  11. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27(2):242–9.

    CAS  PubMed  Google Scholar 

  12. Kong L, Zhang Y, Hu C, et al. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: final results of 2 parallel phase 2 clinical trials. Cancer. 2017;123(12):2258–67.

    CAS  PubMed  Google Scholar 

  13. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology for head and neck cancer, Version 2. 2017. http://www.nccn.org.

  14. Chan ATC, Gregoire V, Lefebvre JL, et al. Nasopharyngeal cancer: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;23(suppl 7):vii83–vii85.

    Google Scholar 

  15. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):47–56.

    CAS  PubMed  Google Scholar 

  16. Vermorken JB, Remenar E, Gorlia T, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–704.

    CAS  PubMed  Google Scholar 

  17. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705–15.

    CAS  PubMed  Google Scholar 

  18. Moher D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264.

    PubMed  Google Scholar 

  19. Higgins JPT, et al. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. 2011. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org.

  20. Gu WJ, Wang F, Tang L, Liu JC. Single-dose etomidate does not increase mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled and observational studies. Chest. 2015;147(2):335–46.

    PubMed  Google Scholar 

  21. Yang Y, Zhang D, Feng N, et al. Increased intake of vegetables, but not fruit, reduce risk for hepatocellular carcinoma: a meta-analysis. Gastroenterology. 2014;147(5):1031–42.

    PubMed  Google Scholar 

  22. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    PubMed  PubMed Central  Google Scholar 

  23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    CAS  PubMed  Google Scholar 

  24. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

    CAS  PubMed  Google Scholar 

  25. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.

    CAS  PubMed  Google Scholar 

  26. Egger M, Smith GD, Schneider M, Minder C. Egger-Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Zeng Z, Yan RN, Tu L, et al. Assessment of concurrent chemoradiotherapy plus induction chemotherapy in advanced nasopharyngeal carcinoma: cisplatin, fluorouracil, and docetaxel versus gemcitabine and cisplatin. Sci Rep. 2018;8(1):15581.

    PubMed  PubMed Central  Google Scholar 

  28. Peng H, Tang LL, Chen BB, et al. Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2018;79:40–6.

    PubMed  Google Scholar 

  29. Frikha M, Auperin A, Tao Y, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006–02). Ann Oncol. 2018;29(3):731–6.

    CAS  PubMed  Google Scholar 

  30. Liu GY, Lv X, Wu YS, et al. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. Cancer Commun. 2018;38(1):21.

    Google Scholar 

  31. Mnejja W, Toumi N, Fourati N, et al. Neoadjuvant chemotherapy with concurrent chemoradiotherapy in the treatment of nasopharyngeal cancer: Southern Tunisian experience. Bull Cancer. 2018;105(5):450–7.

    PubMed  Google Scholar 

  32. Ou D, Blanchard P, ElKhoury C, et al. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. Oral Oncol. 2016;62:114–21.

    CAS  PubMed  Google Scholar 

  33. Kertmen N, Aksoy S, Cengiz M, et al. Comparison of three different induction regimens for nasopharyngeal cancer. Asian Pac J Cancer Prev. 2015;16(1):59–63.

    PubMed  Google Scholar 

  34. Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;20(5):505–10.

    Google Scholar 

  35. Lee AWM, Ngan RKC, Tung SY, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015;121(8):1328–38.

    CAS  PubMed  Google Scholar 

  36. Liang ZG, Zhu XD, Tan AH, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: meta-analysis of 1,096 patients from 11 randomized controlled trials. Asian Pac J Cancer Prev. 2013;14(1):515–21.

    PubMed  Google Scholar 

  37. Song Y, Wang W, Tao G, Zhou X. Survival benefit of induction chemotherapy in treatment for locally advanced nasopharyngeal carcinoma—A time-to-event meta-analysis. Oral Oncol. 2015;51(8):764–9.

    PubMed  Google Scholar 

  38. Chen YP, Guo R, Lin N, et al. Efficacy of the additional neoadjuvant chemotherapy to concurrent chemoradiotherapy for patients with locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis of randomized controlled trials. J Cancer. 2015;6(9):883–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Yan M, Kumachev A, Siu LL, et al. Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis. Eur J Cancer. 2015;51(12):1570–9.

    PubMed  Google Scholar 

  40. Wang MM, Tian H, Li G, et al. Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials. Oncotarget. 2016;7(30):48375–90.

    PubMed  PubMed Central  Google Scholar 

  41. Zheng W, Qiu S, Huang L, Pan J. Is gemcitabine and cisplatin induction chemotherapy superior in locoregionally advanced nasopharyngeal carcinoma? Pak J Med Sci. 2015;31(4):781–6.

    PubMed  PubMed Central  Google Scholar 

  42. Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2016;388(10054):1883–992.

    CAS  Google Scholar 

  43. Wang FZ, Sun QQ, Jiang C, et al. Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma. Oncotarget. 2017;8(57):96798–808.

    Google Scholar 

Download references

Acknowledgements

This study was supported by The National Natural Science Foundation of China (Grant no. 81803569) without any involvement in writing this manuscript.

Author information

Author notes

  1. R. Zhou and J. Zhu contributed equally to this work.

Authors and Affiliations

  1. Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China

    R. Zhou, J. Zhu, Y. Liu, Y. Wang & T. Zhang

  2. Department of General Surgery, Chengdu First People’s Hospital, Chengdu, People’s Republic of China

    X. Chen

Authors
  1. R. Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Zhang.

Ethics declarations

Conflict of interest

The authors certify that there are no conflicts of interest regarding the manuscript.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For the type of study, formal consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOC 39 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, R., Zhu, J., Chen, X. et al. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Clin Transl Oncol 22, 429–439 (2020). https://doi.org/10.1007/s12094-019-02142-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-019-02142-7

Keywords

Search

Navigation